Armata Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

ARMP Armata Pharmaceuticals Inc

BAC Bank of America Corp

TNP Tsakos Energy Navigation Ltd

BFS Saul Centers Inc

ALNY Alnylam Pharmaceuticals Inc

VCNX Vaccinex Inc

XOM Exxon Mobil Corp

ETV Eaton Vance Tax-Managed Buy-Write Opportunities Fund

ASPI ASP Isotopes Inc

ADAG Adagene Inc

Go

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis (NCFB), prosthetic joint infections (PJI) and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.